Lung Cancer - Non-Small Cell News

CancerConsultants provides summaries of new treatment strategies as they are discovered and reported by cancer physicians around the world. Our medical staff attends medical meetings worldwide and reviews medical literature daily to ensure appropriate news is provided to cancer patients and their families in a timely manner.

News of the results of recent clinical trials evaluating cancer therapies and supportive care strategies serve to educate patients regarding new treatment strategies for cancer and facilitate discussions with their doctor. Development of new cancer treatments usually begins in patients with recurrent or metastatic cancers. Once the new treatment appears effective, it is applied to earlier stages of the disease or to patients at higher risk of treatment failure.

Share

Lung Cancer - Non-Small Cell News


Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations (March 29, 2016)

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1... Continue Reading

Alecensa® Delays Cancer Progression Longer Than Xalkori® in Certain Lung Cancers (March 3, 2016)

Interim results from a large clinical trial demonstrated that the targeted agent Alecensa® (alectinib) delays the progression of cancer for a longer period of time than Xalkori® (crizotinib) among patients... Continue Reading

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged... Continue Reading

Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patients, Say Moffitt Cancer Center Researchers (February 22, 2016)

Lung cancer is the most common cause of cancer-related deaths in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new... Continue Reading

Alecensa™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer (December 24, 2015)

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa™ (Alectinib)... Continue Reading

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer (December 3, 2015)

The investigative agent, alectinib, produces high anti-cancer responses among patients with non-small cell lung cancer (NSCLC) that have stopped responding to Xalkori™(crizotinib). These results were... Continue Reading

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer (November 19, 2015)

The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication... Continue Reading

New Lab Test Enables Precision Treatment for Lung Cancer (November 13, 2015)

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide... Continue Reading

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer (November 10, 2015)

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung... Continue Reading

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer (October 19, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC),... Continue Reading

More Lung Cancer - Non-Small Cell News

Latest Lung Cancer - Non-Small Cell News By Stage


Screening/Prevention

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make­up or a tumor’s... Continue Reading

16th World Conference on Lung Cancer Expected to Highlight Advances in Precision Medicine (September 6, 2015)

Today, September 6, the 16th World Conference on Lung Cancer (WCLC) begins in Denver, Colorado. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries... Continue Reading

Changing the Face of Lung Cancer: Live Video Chat about Lung Cancer Screening with the Roswell Park Experts (January 21, 2015)

Cancer screening saves lives, but when it comes to lung cancer, early detection has long been a challenge. Thankfully, the outlook for those at highest risk of this deadly disease is improving thanks to new lung cancer screening techniques. Three leading... Continue Reading

Year in Review: Research News from 2014 in Non-Small Cell Lung Cancer (January 9, 2015)

After several years of developments in lung cancer treatment, more-targeted and more-individualized treatment for non–small cell lung cancer became a reality. Results from studies evaluating ALK-inhibitors continued to show promise in 2014 and initial... Continue Reading

National Lung Cancer Awareness Month on CancerConnect (November 7, 2014)

November 7, 2014 Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of lung cancer programs for national lung cancer awareness month. As the month of November brings lung cancer into focus, it’s time to increase public... Continue Reading

More Screening/Prevention Lung Cancer - Non-Small Cell

Stages I-IIIA

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make­up or a tumor’s... Continue Reading

16th World Conference on Lung Cancer Expected to Highlight Advances in Precision Medicine (September 6, 2015)

Today, September 6, the 16th World Conference on Lung Cancer (WCLC) begins in Denver, Colorado. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries... Continue Reading

EGFR Testing in Advanced Lung Cancer Appears Underutilized (April 28, 2015)

The results of a recent survey suggest that nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) testing before starting treatment. The recent development of drugs that target EGFR has expanded treatment... Continue Reading

Non-Small Cell Lung Cancer: The ALCHEMIST Lung Cancer Trials (January 14, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Year in Review: Research News from 2014 in Non-Small Cell Lung Cancer (January 9, 2015)

After several years of developments in lung cancer treatment, more-targeted and more-individualized treatment for non–small cell lung cancer became a reality. Results from studies evaluating ALK-inhibitors continued to show promise in 2014 and initial... Continue Reading

More Stages I-IIIA Lung Cancer - Non-Small Cell

Stages IIIB-IV

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make­up or a tumor’s... Continue Reading

Alecensa™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer (December 24, 2015)

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa™ (Alectinib) is indicated for advanced, metastatic, ALK-positive... Continue Reading

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer (November 10, 2015)

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published... Continue Reading

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer (October 19, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is divided into... Continue Reading

Iressa® Approved as Initial Therapy for Lung Cancer (September 23, 2015)

The targeted agent Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration (FDA) as initial therapy in the treatment of patients with advanced lung cancer. Specifically, Iressa was approved as initial therapy for the treatment of... Continue Reading

More Stages IIIB-IV Lung Cancer - Non-Small Cell

Recurrent

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make­up or a tumor’s... Continue Reading

Alecensa™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer (December 24, 2015)

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa™ (Alectinib) is indicated for advanced, metastatic, ALK-positive... Continue Reading

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer (December 3, 2015)

The investigative agent, alectinib, produces high anti-cancer responses among patients with non-small cell lung cancer (NSCLC) that have stopped responding to Xalkori™(crizotinib). These results were recently published as a rapid online communication... Continue Reading

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer (November 10, 2015)

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published... Continue Reading

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer (September 15, 2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive, non-small cell lung cancer (NSCLC) who have progressed on or are... Continue Reading

More Recurrent Lung Cancer - Non-Small Cell

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS